NCT01009814View on ClinicalTrials.gov

Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 23, 2009

Primary Completion Date

June 25, 2010

Study Completion Date

June 25, 2010

Conditions
HIV Infections
Interventions
DRUG

BMS-663068

BMS-663068 will be administered as a tablet formulation

DRUG

Ritonavir

Ritonavir will be administered as a capsule.

Trial Locations (1)

13353

GSK Investigational Site, Berlin

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY